Blood Loss and Time to Ambulation Decreased in Lumbar Interbody Fusion Patients with TXA vs Placebo .
Tranexamic Acid for Blood Loss after Transforaminal Posterior Lumbar Interbody Fusion Surgery: A Double-Blind, Placebo-Controlled, Randomized Study.
Biomed Res Int. 2020 Aug 14;2020:8516504Forty patients undergoing transforaminal lumbar interbody fusion were randomized into receiving tranexamic acid or a placebo. Outcomes of interest included blood loss, postoperative drainage volume, time to drainage removal, time to ambulation, length of hospital stay, hemoglobin (Hb) levels post-operation, and the incidence of adverse events. Results demonstrated that intraoperative blood loss was significantly in favour of the TXA group, as well as time to ambulation. No significant differences between the TXA and control groups were observed in postoperative drainage, time to drainage removal, length of hospital stay post-operation, post-operative hemoglobin levels, or the incidence of adverse events.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
